Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Galectin Therapeutics Company Profile (NASDAQ:GALT)

Consensus Ratings for Galectin Therapeutics (NASDAQ:GALT) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $15.00 (175.23% upside)

Analysts' Ratings History for Galectin Therapeutics (NASDAQ:GALT)
Show:
DateFirmActionRatingPrice TargetDetailsShare
8/1/2014AegisDowngradeBuy -> HoldViewTweet This Rating  Share This Rating on StockTwits
7/29/2014BMO Capital MarketsReiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
7/29/2014MLV & Co Lower Price TargetBuy$27.00 -> $15.00ViewTweet This Rating  Share This Rating on StockTwits
6/23/2014AegisReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
4/2/2014MLV & Co Boost Price TargetBuy$20.00 -> $27.00ViewTweet This Rating  Share This Rating on StockTwits
2/10/2014AegisBoost Price TargetBuy$16.00 -> $32.00ViewTweet This Rating  Share This Rating on StockTwits
1/9/2014AegisBoost Price TargetBuy$10.00 -> $16.00ViewTweet This Rating  Share This Rating on StockTwits
12/3/2013MLV & Co Initiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
10/7/2013Ascendiant Capital MarketsInitiated CoverageBuy$13.00ViewTweet This Rating  Share This Rating on StockTwits
8/19/2013AegisBoost Price TargetBuy$7.00 -> $10.00ViewTweet This Rating  Share This Rating on StockTwits
3/5/2013AegisReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/31/2012 forward)
Discuss Galectin Therapeutics